MIMM 387. The Business of Science.

The ability to select and manipulate genetic material has led to unprecedented interest in the industrial applications of procaryotic and eucaryotic cells. Beginning in the 1970s the introduction of and subsequent refinements to recombinant DNA technology and hybridoma technology transformed the horizons of the biopharmaceutical world. This course will highlight the important events that link basic research to clinical/commercial application of new drugs and chemicals.